abrdn Healthcare Opportunities Fund Shares of Beneficial Interest (THQ)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 40/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- abrdn Healthcare Opportunities Fund (THQ) and abrdn World Healthcare Fund (THW) Announce New Managed Distribution Policies and Declare Monthly Distributions
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
- /C O R R E C T I O N -- Aberdeen Investments U.S. Closed End Funds/
- ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for abrdn Healthcare Opportunities Fund Shares of Beneficial Interest.
Full THQ Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.